An observational study in Aneuploidy and Trisomy 21, sponsored by Roche Sequencing Solutions. Completed at 6 sites in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-10.
Sponsored by Roche Sequencing Solutions (part of Hoffmann-La Roche) · Observational
Among 31 studies in Aneuploidy with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Aneuploidy · United States.
Among the 31 studies in Aneuploidy with a site in United States, this one is the 4th largest by enrollment of the 17 observational ones, is one of 2 that started in 2010, is one of 17 observational ones, and was the 6th registered.
73 studies on the registry are indexed under Aneuploidy; 10 are open to participants now.
This study's enrollment of 4,000 is above the median of 325 across 38 observational studies indexed under Aneuploidy.
Browse Aneuploidy studies →6 of the 31 studies in Aneuploidy with a site in United States are open now, in 2 countries. Each count lists the studies.
Of the 8 Aneuploidy studies recruiting now, 5 (63%) set no upper age limit and 3 (38%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 60 Years · female · healthy volunteers too.
The full table on the hub →31 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2010.
Median enrollment 202 across the 14 interventional studies, 2,000 across the 17 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Roche Sequencing Solutions is the lead sponsor of 2 studies on the registry; none are open to participants now.
Roche Sequencing Solutions has 1 study filed under Aneuploidy — fewer than ten, so there is no comparison to draw.
1 of the studies in Aneuploidy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369362MotilityCount apsTo Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That Develop to the Point That They Are Able to be Transferred) in IVF Cycles. | 2027-03-20 |
Among the 31 studies in Aneuploidy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
The purpose of this study is to develop and evaluate a blood test for pregnant women for detection of fetal aneuploidy.
Pregnant women planning to undergo chorionic villus sampling or amniocentesis for fetal genetic evaluation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comparison of blood test to results from chorionic villus sampling or amniocentesis for fetal aneuploidy detection
Circulating genomic material from maternal blood will be quantified using biochemical techniques to determine the presence of fetal aneuploidy. The results obtained from analysis of circulating genomic material will be compared to the karyotype results from chorionic villus sampling or amniocentesis.
Time frame: 24 months
The record gives a start of Aug 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.